Inhibition of Ras and related G-proteins as a therapeutic strategy for blocking malignant glioma growth

Neurosurgery

Volumn 43, Issue 1, 1998, Pages 124-132

  Bredel, Markus ^a   Pollack, Ian F ^a,d   Freund, John M ^a   Hamilton, Andrew D ^b   Sebti, Said M ^c  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

Astrocytoma; Farnesyltransferase inhibition; Geranylgeranyltransferase inhibition; Malignant glioma; Ras; Signal transduction

Indexed keywords

ANTINEOPLASTIC AGENT; GERANYLTRANSFERASE; GGTI 286; GGTI 298; GUANINE NUCLEOTIDE BINDING PROTEIN; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE METHYL ESTER; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN INHIBITOR; RAS PROTEIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CLONOGENIC ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; PRENYLATION; PRIORITY JOURNAL;

BENZAMIDES; CELL DIVISION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; GLIOMA; GTP-BINDING PROTEINS; HUMANS; METHIONINE; PROTEIN ISOPRENYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS P21(RAS); TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY;

EID: 0031834918     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006123-199807000-00081     Document Type: Article

References (56)

1. Aaronson SA: Growth factors and cancer. Science 254:1146-1153, 1991.
2. Barbacid M: ras genes. Annu Rev Biochem 56:779-827, 1987.
3. Borowski P, Kornetzky L, Heiland M, Roloff S, Weber W, Laufs R: Characterization of the C-terminal domain of Ras-GTPase-activating protein (Ras-GAP) as substrate for epidermal growth factor receptor and p60 (c-src) kinase. Biochem Mol Biol Int 39:635-646, 1996.
4. Caldas C, Kern SE: K-ras mutations and pancreatic adenocarcinoma. Int J Pancreatol 18:1-6, 1995.
5. ras is modified by a farnesyl isoprenoid. Proc Natl Acad Sci U S A 86:8323-8327, 1989.
6. ras-generated signals towards cell growth or apoptosis is determined by protein kinase C and Bcl-2. Oncogene 11:1487-1498, 1995.
7. Clark GJ, Kinch MS, Rogers-Graham K, Sebti SM, Hamilton AD, Der CJ: The Ras-related protein Rheb is farnesylated and antagonizes Ras signaling and transformation. J Biol Chem 272:16093-16095, 1997.
8. Fernandes RS, McGowan AJ, Cotter TG: Mutant H-ras overexpression inhibits drug and U.V. induced apoptosis. Anticancer Res 16:1691-1705, 1996.
9. Gerosa MA, Talarico D, Fognani C, Raimondi E, Colombatti M, Tridente G, De Carli L, Delia Valle G: Overexpression of N-ras oncogene and epidermal growth factor receptor gene in human glioblastomas. J Natl Cancer Inst 81:63-67, 1989.
10. Gibbs JB, Oliff A, Kohl NE: Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic. Cell 77:175-178, 1994.
11. Gomez J, Martinez C, Fernandez B, Garcia A, Rebollo A: Critical role of Ras in the proliferation and prevention of apoptosis mediated by IL-2. J Immunol 157:2272-2281, 1996.
12. Guha A, Lau N, Pawson A: Ras-mediated proliferation of human astrocytoma cells. Proc Annu Meet Am Assoc Cancer Res 36:173, 1995 (abstr).
13. ras. Oncogene 12:2121-2127, 1996.
14. Harris CC, Hollstein M: Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 329:1318-1327, 1993.
15. Klingshoffer RA, Duckworth B, Valius M, Cantley L, Kazlauskas A: Platelet-derived growth factor-dependent activation of phosphatidylinositol 3-kinase is regulated by receptor binding of SH2-domain-containing proteins which influence Ras activity. Mol Cell Biol 16:5905-5914, 1996.
16. Kohl NE, Conner MW, Gibbs JB, Graham SL, Hartman GD, Oliff A: Development of inhibitors of protein farnesylation as potential chemotherapeutic agents. J Cell Biochem 22:145-150, 1995.
17. Kohl NE, Mosser SD, DeSolms SJ, Giuliani EA, Pomliano DL, Graham SL, Smith RL, Scolnick EM, Oliff A, Gibbs JB: Selective inhibition of Ras-dependent transformation by a farnesyltransferase inhibitor. Science 260:1934-1937, 1993.
18. Kohl NE, Omer CA, Conner MW, Anthony NJ, Davide JP, deSolms SJ, Guiliani EA, Gomez RP, Graham SL, Hamilton K, Handt LK, Hartman GD, Koblan KS, Krai AM, Miller PJ, Mosser SO, O'Neill TJ, Rands E, Schaber MD, Gibbs JB, Oliff A: Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in Ras transgenic mice. Nat Med 1:792-797, 1995.
19. Kohl NE, Wilson FR, Mosser SD, Giuliani E, DeSolms SJ, Conner MW, Anthony NJ, Holtz WJ, Gomez RP, Lee TJ, Smith RL, Graham SL, Hartman G, Gibbs JB, Oliff A: Protein farnesyltransferase inhibitors block the growth of Ras-dependent tumors in nude mice. Proc Natl Acad Sci U S A 91:9141-9145, 1994.
20. Lebowitz PF, Casey PJ, Prendergrast GC, Thissen JA: Farnesyltransferase inhibitors alter the prenylation and growth stimulating function of RhoB. J Biol Chem 272:15591-15594, 1997.
21. Lebowitz PF, Sakamuro D, Prendergrast GC: Farnesyl transferase inhibitors induce apoptosis of Ras-transformed cells denied substratum attachment. Cancer Res 57:708-713, 1997.
22. Lerner EC, Qian Y, Blaskovitch MA, Fossum RD, Vogt A, Sun J, Cox AD, Der CJ, Hamilton AD, Sebti SM: Ras CAAX peptidomimetic FTI-277 blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes. J Biol Chem 270:26802-26806, 1995.
23. Lerner EC, Qian Y, Hamilton AD, Sebti SM: Disruption of oncogenic K-Ras4B processing and signaling by a potent geranylgeranyltransferase I inhibitor. J Biol Chem 270:26770-26773, 1995.
24. Libermann TA, Nusbaum HR, Razon N, Kris R, Lax I, Soreq H, Whittle N, Waterfield MD, Ullrich A, Schlessinger J: Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumors of glial origin. Nature 313:144-147, 1985.
25. Lowe S, Bodis S, McClatchy A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T: p53 status and the efficacy of cancer therapy in vivo. Science 266:807-810, 1994.
26. Lowy DR, Willumsen BM: Function and regulation of Ras. Annu Rev Biochem 62:851-891, 1993.
27. Macara IG, Lounsbury KM, Richards SA, McKiernan C, Bar-Sagi D: The Ras superfamily of GTPases. FASEB J 10:625-630, 1996.
28. 2-M enrichment in A549 cells. Cancer Res 57:1846-1850, 1997.
29. Nagasu T, Yoshimatsu K, Rowell C, Lewis MD, Garcia AM: Inhibition of human tumor xenograft growth by treatment with farnesyl transferase inhibitor B956. Cancer Res 55:5310-5314, 1995.
30. Newman CM, Magee AI: Posttranslational processing of the Ras superfamily of small GTP-binding proteins. Biochim Biophys Acta 1155:79-96, 1993.
31. Nooter K, Boersma AW, Oostrum RG, Burger H, Jochemsen AG, Stoter G: Constitutive expression of the c-H-ras oncogene inhibits doxorubicin-induced apoptosis and promotes cell survival in a rhabdomyosarcoma cell line. Br J Cancer 71:555-561, 1995.
32. Ohmori M, Shirasawa S, Furuse M, Okumura K, Susazuki T: Activated Ki-Ras enhances sensitivity of ceramide-induced apoptosis without c-jun NH2-terminal kinase/stress-activated protein kinase or extracellular signal-regulated kinase activation in human colon cancer cells. Cancer Res 57:4714-4717, 1997.
33. Orian JM, Vasilopoulos K, Yoshida S, Kaye AH, Chow CW, Gonzales MF: Overexpression of multiple oncogenes related to histopathological grade of astrocytic glioma. Br J Cancer 66:106-112, 1992.
34. Peddanna N, Mendis R, Holt S, Verma RS: Genetics of colorectal cancer. Int J Oncol 9:327-335, 1996.
35. Pollack IF, Randall MS, Kristofik MP, Kelly RH, Selker RG, Vertosick FT Jr: Response of malignant glioma cell lines to epidermal growth factor and platelet-derived growth factor in a serum-free medium. J Neurosurg 73:98-105, 1990.
36. Pollack IF, Randall MS, Kristofik MP, Kelly RH, Selker RG, Vertosick FT Jr: Response of low-passage human gliomas in vitro to stimulation and selective inhibition of growth factor-mediated pathways. J Neurosurg 75:284-293, 1991.
37. Prigent SA, Nagane M, Lin H, Huvar I, Boss GR, Feramisco JR, Cavenee WK, Huang HJS: Enhanced tumorigenic behavior of glioblastoma cells expressing a truncated epidermal growth factor receptor is mediated through the Ras-SHC-GRB2 pathway. J Biol Chem 271:25639-25645, 1996.
38. Riccardi A, Danova M, Giordano M, Gaetani P, Butti G, Zibera C, Mazzini G: Proto-oncogene expression and proliferative activity in human malignant gliomas. Dev Oncol 66:81-84, 1991.
39. Riss TL, Moravec RA: Comparison of MTT, XTT, and an novel tetrazolium compound MTS for in vitro proliferation and chemosensitivity assays. Mol Biol Cell 3 [Suppl]:184, 1992 (abstr).
40. Roche S, McGlade J, Jones M, Gish GD, Pawson T, Courtneidge SA: Requirement of phospholipase C-gamma, the tyrosine phosphatase Syp and the adaptor proteins Shc and Nek for PDGF-induced DNA synthesis: Evidence for the existence of Ras-dependent and Ras-independent pathways. EMBO J 15:4940-4948, 1996.
41. Salgaller M, Agius L, Yates A, Pearl D, Roberts W, Stephens R: Application of automated image analysis to demonstrate the correlation between Ras p21 expression and severity of gliomas. Biochem Biophys Res Commun 169:482-491, 1990.
42. Schmitz GG, Walter T, Seibl R, Kessler C: Nonradioactive labeling of oligonucleotides in vitro with the hapten digoxigenin by tailing with terminal transferase. Anal Biochem 192:222-231, 1991.
43. Sebti SM, Hamilton AD: Inhibition of Ras prenylation: A novel approach to cancer chemotherapy. Pharmacol Ther 74:103-114, 1997.
44. Sebti S, Hamilton AD: Inhibitors of prenyl transferases. Curr Opin Oncol 9:557-561, 1997.
45. Sepp-Lorenzino L, Ma Z, Rands E, Kohl NE, Gibbs JB, Oliff A, Rosen N: A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Cancer Res 55:5302-5309, 1995.
46. Sun J, Qian Y, Hamilton AD, Sebti SM: Ras CAAX peptidomimetic FTI-276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-ras mutation and p53 deletion. Cancer Res 55:4243-4247, 1995.
47. Tamanoi F: Inhibitors of Ras farnesyltransferases. Trends Biochem Sci 18:349-353, 1993.
48. Van Meir EG, Kikuchi T, Tada M, Li H, Diserens AC, Wojcik BE, Huang HJ, Friedmann T, de Tribolet N, Cavenee WK: Analysis of the p53 gene and its expression in human glioblastoma cells. Cancer Res 54:649-652, 1994.
49. Vogt A, Qian Y, McGuire TF, Hamilton AD, Sebti SM: Protein geranylgeranylation, not farnesylation, is required for the G1 to S phase transition in mouse fibroblasts. Oncogene 13:1991-1999, 1996.
50. WAF1/CIP1/SDI1 in a p53-independent manner. J Biol Chem 272:27224-27229, 1997.
51. Westermark B, Heldin CH, Nister M: Platelet-derived growth factor in human glioma. Glia 15:257-263, 1995.
52. Westphal M, Brunken M, Rhode E, Herrmann H-D: Growth factors in cultured human glioma cells: Different effects of FGF, EGF, and PDGF. Cancer Lett 38:283-296, 1988.
53. White E, Chiou SK, Rao L, Sabbatini P, Lin HJ: Control of p53-dependent apoptosis by E1B, Bcl-2, and Ha-Ras proteins. Cold Spring Harb Symp Quant Biol 59:395-402, 1994.
54. ras C-terminus is required for transformation and membrane association. Nature 310:583-586, 1984.
55. Wong AJ, Bigner SH, Bigner DD, Kinzler KW, Hamilton SR, Vogelstein B: Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci U S A 84: 6899-6903, 1987.
56. Wyllie AH: The genetic regulation of apoptosis. Curr Opin Genet Dev 5:97-104, 1995.